Litcius/Paper detail

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

Ieva Saulīte, Desislava Ignatova, Yun‐Tsan Chang, Christina Fassnacht, Florentia Dimitriou, Eleni Maria Varypataki, Florian Anzengruber, Mirjam Nägeli, Antonio Cozzio, Reinhard Dummer, Julia Scarisbrick, Steve Pascolo, Wolfram Hoetzenecker, Małgorzata Bobrowicz, Emmanuella Guenova

2020OncoImmunology62 citationsDOIOpen Access PDF

Abstract

resulted in reduced Th2 phenotype of non-tumor T lymphocytes, but enhanced the proliferation of tumor T cells from SS patients. Our study sheds some light on the PD-1 axis in both peripheral blood and skin compartments in SS patients, which may be relevant for the treatment of L-CTCL with immune checkpoint inhibitor.

Topics & Concepts

BlockadeCancer researchPhenotypeProgrammed cell death 1T cellMedicinePD-L1BiologyImmunologyImmunotherapyReceptorInternal medicineImmune systemGeneBiochemistryCutaneous lymphoproliferative disorders researchCAR-T cell therapy researchFungal Infections and Studies
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation | Litcius